- Ticker
- ACE.ST
- Price
- 4.47
- Stock movement down
- -0.18 (-3.97%)
- Company name
- Ascelia Pharma AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 150.90M
- Ent value
- 153.60M
- Price/Sales
- -
- Price/Book
- 2.40
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.43%
- 1 year return
- -70.97%
- 3 year return
- -50.27%
- 5 year return
- -26.19%
- 10 year return
- -
Last updated: 2024-07-23
DIVIDENDS
ACE.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 2.40 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 33.76M |
| EPS (TTM) | -2.63 |
| FCF per share (TTM) | -3.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -92.16M |
| Net income (TTM) | -88.76M |
| EPS (TTM) | -2.63 |
| EPS (1y forward) | -1.79 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 26.54M |
| Net receivables | 4.42M |
| Total current assets | 34.22M |
| Goodwill | 0.00 |
| Intangible assets | 57.08M |
| Property, plant and equipment | 828.00K |
| Total assets | 92.13M |
| Accounts payable | 1.09M |
| Short/Current long term debt | 18.80M |
| Total current liabilities | 11.21M |
| Total liabilities | 29.25M |
| Shareholder's equity | 62.88M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -104.31M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -104.31M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -141.16% |
| Return on Assets | -96.35% |
| Return on Invested Capital | -108.76% |
| Cash Return on Invested Capital | -127.82% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.66 |
| Daily high | 4.66 |
| Daily low | 4.28 |
| Daily Volume | 84K |
| All-time high | 63.10 |
| 1y analyst estimate | 17.00 |
| Beta | 1.09 |
| EPS (TTM) | -2.63 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 15 Aug 2024 |
Downside potential
Loading...
Downside potential data
| ACE.ST | S&P500 | |
| Current price drop from All-time high | -92.92% | -1.81% |
| Highest price drop | -95.74% | -56.47% |
| Date of highest drop | 30 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -52.56% | -11.26% |
| Avg time to new high | 75 days | 12 days |
| Max time to new high | 908 days | 1805 days |
COMPANY DETAILS
Marketcap
150.90M
Marketcap category
Small-cap
Description
Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 trial for the treatment of gastric cancer. Ascelia Pharma AB (publ) was incorporated in 1999 and is based in Malmö, Sweden.
Employees
13
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found